

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Currently Amended) ~~The isolated nucleic molecule of claim 1, wherein said~~
An isolated nucleic acid molecule comprising a polynucleotide is having SEQ ID NO: 47
~~and functional variants thereof or a functional variant thereof having at least 95%~~
identity to SEQ ID NO: 47, wherein said polynucleotide and functional variant thereof
confer vascular-preferred polynucleotide transcription.
3. (Canceled)
4. (Currently Amended) An isolated polynucleotide having a sequence selected
from
 - (a) sequences complementary to any of the sequences in claim 2; and
 - (b) sequences that are reverse complements to any of the sequences in claim 2,**wherein said sequence is at least 30 nucleotides in length and confers vascular-preferred**
polynucleotide transcription.
5. (Previously Presented) The isolated nucleic molecule of claim 2,
wherein said polynucleotide confers xylem-preferred gene expression in a plant cell.
6. (Previously Presented) The isolated nucleic molecule of claim 2,
wherein said polynucleotide is capable of upregulating or downregulating the expression of
an operably-linked gene in a plant cell.
- 7-20. (Canceled)